Medication questions Dutasteride
Is dutasteride licensed for hair loss in the UK?
Short answer
No. In the UK, dutasteride (Avodart and generic versions) is licensed only to treat an enlarged prostate, known as benign prostatic hyperplasia. A doctor can still prescribe it for male pattern hair loss, but that is off-label use, meaning outside the licence. The prescriber takes responsibility and must explain the off-label use and known risks before you decide.
Key facts
- UK licence: benign prostatic hyperplasia (enlarged prostate) only.
- Use for hair loss is off-label; the prescriber must explain this and the known risks.
- Half-life about 3 to 5 weeks; blood donation deferred for 6 months.
- MHRA precautionary mood warning added on 11 May 2026.
What the UK licence covers
The Avodart summary of product characteristics (SmPC), the official prescribing information approved by the MHRA, lists its uses as the "treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH)" and reducing the risk of urinary retention and surgery. Hair loss is not among them. The SmPC notes that its effect on hair "was not formally studied during the phase III programme".
A licence (marketing authorisation) covers the uses a manufacturer applied for and supported with evidence. The British Association of Dermatologists explains that licences are awarded "following a rigorous process of evaluation by the MHRA, following an application by a pharmaceutical company". A medicine not being licensed for a use is not the same as being banned for it. Our glossary entry on the SmPC explains what the document is.
What off-label means
The MHRA defines off-label use as "use of a licensed medicine outside the terms defined by the licence (eg, outside defined indications, doses, routes of administration, or contrary to listed warnings)". Dutasteride for hair loss is off-label because hair loss is outside its licensed indication.
This is different from an unlicensed special, which is a medicine with no UK licence at all, made to order, such as a compounded topical. Dutasteride capsules are a licensed medicine being used for an unlicensed purpose. Our off-label glossary page covers the distinction.
How prescribers handle off-label prescribing
The MHRA sets out what a prescriber should do. They should be satisfied there is "a sufficient evidence base and/or experience of using the medicine to show its safety and efficacy", take "responsibility for prescribing the medicine and for overseeing the patient's care", and record what was prescribed and why.
They must also give you "sufficient information about the proposed treatment, including known serious or common adverse reactions, to enable them to make an informed decision".
At WMG Meds, dutasteride may be considered where finasteride has not given an adequate response. A GMC-registered doctor reviews your assessment, explains the off-label use, the MHRA advice and handling precautions before any prescription, and reviews you at follow-up. Our news guide to dutasteride covers the process in more detail.
What to know before considering it
Long half-life. Dutasteride's half-life is about 3 to 5 weeks, so it takes months to clear. See stopping dutasteride.
MHRA warning. The Drug Safety Update of 11 May 2026 added a precautionary warning that depression and suicidal thoughts have been reported with finasteride, a medicine in the same class, because data for dutasteride were very limited. The Avodart leaflet lists erection problems, lower sex drive and ejaculation problems as common, each of which "may continue after you stop taking Avodart".
Men only. It must not be taken by women, children or adolescents. Pregnant women must not handle leaking capsules.
Prostate tests. It lowers PSA by about 50% after 6 months. The leaflet also notes that in a study of men at increased risk of prostate cancer, men taking Avodart had a serious form of prostate cancer more often, and that the effect of Avodart on this is not clear.
Blood donation. No donating within 6 months of the last dose.
If you are weighing it up, the free online assessment is the starting point, and a doctor will tell you if it is not appropriate.
Want an answer for your own situation?
A GMC-registered doctor can review your history and medicines and tell you what would suit you, including whether treatment is right for you at all. The assessment and review are free.
Start your free assessment →Related questions
Is it legal to be prescribed dutasteride for hair loss?
Yes. UK prescribers can prescribe a licensed medicine off-label when they judge it appropriate, provided they take responsibility, record their reasons and give you enough information about the treatment and its risks to make an informed decision.
Why is dutasteride not licensed for hair loss in the UK?
A licence covers the uses a manufacturer has applied for and supported with evidence. Avodart is licensed for an enlarged prostate, and its effect on hair was not formally studied in the trials for that licence.
Does off-label mean unsafe?
No, but it does mean the specific use has not been assessed for a licence, so the prescriber carries more responsibility for the decision. The known side effects and warnings for dutasteride still apply, and should be explained to you before you start.
What dose of dutasteride is used for hair loss?
Each capsule contains 0.5 mg. There is no licensed hair loss regimen, so your prescriber decides how you take it. Capsules should be swallowed whole, not chewed or opened.
Can women take dutasteride for hair loss?
No. The UK product information says it is for men only and must not be taken by women, children or adolescents.
Sources
- Avodart 0.5 mg soft capsules: summary of product characteristics (eMC, revised 11 August 2026)
- Avodart 0.5 mg soft capsules: patient information leaflet (eMC, revised March 2026)
- MHRA Drug Safety Update: Off-label or unlicensed use of medicines, prescribers' responsibilities
- MHRA Drug Safety Update, 11 May 2026: Finasteride and dutasteride, updated safety warnings
- British Association of Dermatologists: Hair loss, female pattern (patient information leaflet, October 2024), section on unlicensed and off-licence use
Facts checked against these sources on 4 October 2026. This page is general information, not personal medical advice. Read our editorial policy.